Aptose Biosciences Inc. (TSE:APS – Get Free Report) (NASDAQ:APTO) dropped 19.2% during trading on Thursday . The stock traded as low as C$0.20 and last traded at C$0.21. Approximately 118,303 shares changed hands during mid-day trading, an increase of 208% from the average daily volume of 38,415 shares. The stock had previously closed at C$0.26.
Aptose Biosciences Trading Down 14.5 %
The company has a quick ratio of 5.41, a current ratio of 1.05 and a debt-to-equity ratio of -117.37. The business’s fifty day moving average is C$0.30 and its 200 day moving average is C$0.43. The stock has a market cap of C$10.12 million, a PE ratio of -0.05 and a beta of 1.36.
Aptose Biosciences Company Profile
Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.
See Also
- Five stocks we like better than Aptose Biosciences
- Differences Between Momentum Investing and Long Term Investing
- 3 Stocks Poised to Thrive as NVIDIA Dominates the AI Boom
- What Are Growth Stocks and Investing in Them
- MercadoLibre: High-Growth EM Stock With 100% Upside Potential
- 3 Grocery Stocks That Can Help Take a Bite Out of Inflation
- As the Magnificent 7 Stalls, These 3 Stocks Are Gaining Momentum
Receive News & Ratings for Aptose Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptose Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
